Clinical Trial Access for Advanced Breast Cancer in India

This page is information, not medical advice. It cannot tell you whether a trial suits you, and it is not a referral. Trial eligibility turns on your pathology, receptor and biomarker status, prior treatment lines, organ function and performance status, none of which an article can know. Use it to arrive at a consultation with specific protocols and better questions.

There is no single service in India that matches a patient to a breast cancer trial. Access runs through several separate things: two free public registries you can search yourself, a coordinating network spanning member hospitals, the trial units at the large centres, remote tumour board services, and genomic testing that opens biomarker-defined protocols. Every one of them needs a clinician to read your file before it goes anywhere.

The first step costs nothing and does not need an appointment. The Clinical Trials Registry - India and ClinicalTrials.gov both let you filter by condition and recruitment status. Bringing specific trial identifiers and your records to a consultation changes the question from "is there anything else" to "am I eligible for this one".

Key points

• Two registries are free, public and searchable before you have seen anyone: CTRI, which carries investigator-initiated studies at Indian centres that often never reach the global database, and ClinicalTrials.gov, which is broader but lists many trials with no Indian site.
• The National Cancer Grid links more than 300 member centres and anchors an 11-site clinical trial network with Tata Memorial Centre as lead site, so a protocol open at one member hospital can sometimes be reached through another.
• Genomic testing is what opens biomarker-defined trials, and it is often the missing piece. It does not always have to be bought in advance: some protocols perform molecular testing during screening, so ask the trial team what they require and fund before paying for a panel.
• Be careful what you expect from "AI trial matching". At least one Indian precision-oncology platform markets trial optimisation to pharmaceutical sponsors, not to patients, which is a different product entirely.
• Sponsors usually fund the investigational drug and protocol-mandated tests, while travel, accommodation, caregiver time and standard-of-care components are typically yours. Reimbursement of travel and incidental expenses is permitted with ethics committee approval, so ask for the study's written policy rather than assuming.

What each route actually does

Route	What it is	What it does for you	Cost to you
CTRI	India's statutory trial registry	Lists Indian studies, including investigator-initiated ones absent from global databases	Free
ClinicalTrials.gov	US-run global registry	Broader coverage; many listings have no Indian site, so check enrolment locations	Free
National Cancer Grid	Coordinating network, 300+ centres	Multi-centre protocols and twice-weekly virtual tumour boards across members	Free to access; treatment billed by the hospital
Tata Memorial Centre / ACTREC	High-volume trial unit	Runs Phase I to IV protocols; ask the department for the investigator on a given study	Navigation free; sponsor usually funds trial drug
Navya	Remote tumour board service	Written multidisciplinary opinion without travelling	Free for qualifying patients, otherwise paid
4baseCare	Genomic profiling lab	Tissue, ctDNA, dual-source, HRD and germline testing that defines biomarker eligibility	Cost of the panel
An independent oncologist	Second opinion	Subtype-specific read of an existing plan	Consultation fee

Start with your treating oncologist

Every route below needs someone to review your pathology, staging and prior treatment lines, and to make the referral. A registry search does not enrol you in anything. It gives your oncologist something specific to assess.

If your current plan was set before your most recent progression, or before genomic testing, eligibility may need reassessing against the file as it stands now.

Raising it can feel awkward if your oncologist has not brought trials up, and plenty of people worry it sounds like a vote of no confidence. A direct, unloaded way to put it: "Are there any trials I might be eligible for, here or anywhere else, and if not, what rules me out?" The second half is the useful half. A clear answer (too few prior lines, the wrong receptor status, performance status below the threshold, no site within reach) tells you whether to keep looking or to stop spending energy on it.

If the answer is vague, that is a reason to seek a second opinion rather than to argue. Keeping track of which protocols are open is a specialised and time-consuming task, and not every practice does it.

The two registries, and how to search them

CTRI (ctri.nic.in) is India's statutory registry, maintained by the Indian Council of Medical Research. The drug regulator requires registration before a trial enrols its first participant, but ICMR runs the registry itself. That makes CTRI the better record for investigator-initiated studies at Indian centres and regional cancer centres, which frequently never appear on the global database. Note that registration is a disclosure requirement, not an endorsement: CTRI does not authenticate the documents submitted to it, so a registration number tells you a trial exists on the record, not that it is safe or suitable.

ClinicalTrials.gov is larger and better organised, and it surfaces international biomarker-specific protocols, for example studies restricted to hormone-receptor-positive, HER2-negative disease with a PIK3CA mutation. The trap is assuming availability: a great many listings have no Indian enrolment site at all. Open the locations section of every listing before you get attached to it.

A workable sequence:

1. Search CTRI for your condition, and note the CTRI reference numbers.
2. Search ClinicalTrials.gov for the same condition with India as the location filter and recruitment status set to recruiting. Note the NCT numbers. A study's overall status and an individual site's status can differ, so confirm the specific Indian site is recruiting before planning any travel.
3. For each NCT number, open the locations list and confirm there is a site you can physically reach.
4. Check the trial page of the hospital you are considering. Tata Memorial publishes its active studies, and some protocols appear only there.
5. For each candidate, write down the protocol number, the site, the named contact and the one or two eligibility criteria you are unsure about.
6. Re-check recruitment status a day or two before your appointment. It changes.

That last point matters more than it sounds. Recruitment can close while screening is in progress, and the screening itself can take weeks.

National Cancer Grid

The National Cancer Grid links more than 300 cancer centres across India and sets shared treatment guidelines used across that network. For trials specifically, it anchors a clinical trial network established in late 2020 with the Biotechnology Industry Research Assistance Council, built as an 11-site consortium of public and private centres with Tata Memorial Centre, Mumbai as the lead site.

It also runs virtual tumour boards twice a week, where oncologists from member centres review complex cases together over video, with roughly 25 participants in a typical session.

What that gives you in practice: if you are being treated at a member centre, your case can be discussed against the wider network rather than one hospital's own trial list, and a referral from one member centre is read in a familiar format at another.

The network also publishes a contact route for trial queries on its clinical trial network page, so you can ask directly whether a protocol is recruiting. What a contact desk cannot do is assess you: eligibility still runs through a clinician with your file.

Tata Memorial Centre and ACTREC

ACTREC's medical oncology department serves over 300 patients daily in its outpatient clinics and administers more than 150 chemotherapy sessions a day. Its published portfolio covers globally sponsored and investigator-initiated studies spanning Phase I, Phase I/II, Phase II, Phase III and Phase IV.

The department does not publish a patient-navigator team you can ring to be matched, though it is often described as having one. Published contact details are uneven: several haematology studies name an individual contact, while the solid tumour entries generally do not. Identify the protocol first, then ask the department how to reach that study's investigator rather than going through the general outpatient desk.

The costs of this route are waiting, formal referral, screening investigations and travel, plus eligibility criteria you may not meet.

Navya

Navya is a clinical informatics service built with Tata Memorial Centre and the National Cancer Grid to deliver a multidisciplinary opinion to patients who cannot travel for one. You submit reports, and a panel review comes back as a written treatment plan, generally within a few days rather than the weeks a sequence of in-person consultations takes.

On accuracy, be precise about what is known. Navya's own materials and the coverage repeating them report concordance with in-person tumour board decisions in the range of 97 to 99 percent, including a validation exercise against tumour board decisions at Tata Memorial. Those figures come from the company, conference abstracts and press coverage rather than a fully published independent study, so treat them as a claim the company stands behind rather than a settled finding.

Cost is worth checking before assuming it is out of reach. Navya's published pricing sets out a free tier for qualifying patients, including families below an annual income threshold and patients referred through specified hospital and NGO categories.

It is an opinion service, not an enrolment route: it can identify a specific trial worth asking about, but a site still has to screen you.

4baseCare, and what "AI trial matching" does not mean

4baseCare is a Bengaluru precision-oncology company running comprehensive genomic profiling, with laboratories in India and abroad. Its test menu is the part that matters for trial access:

• Tissue profiling from FFPE blocks, covering tumour DNA and RNA
• Liquid profiling, which is circulating tumour DNA from blood
• A dual-source option combining tissue, liquid and germline analysis to separate true somatic variants
• HRD testing, which measures genomic instability. Read this carefully in breast cancer: HRD positivity on its own does not establish eligibility for an approved PARP inhibitor, whose breast indications are tied to specific gene mutations. It is used for trial selection and for discussion with your oncologist, not as a licence
• Germline testing for inherited variants, relevant to PARP inhibitor eligibility and to family risk

That profile is what makes you assessable for biomarker-defined protocols, such as a study restricted to a PIK3CA mutation. It does not always have to pre-exist, though: some trials carry out the molecular testing inside their own screening process.

Be precise about what the trial-related parts do. The company says a genomic report may list clinical trial opportunities relevant to the findings, which is useful as a starting list. Separately, its OncoTwin platform has a module called clinical trial optimisation, and that one is aimed at pharmaceutical sponsors: trial design, feasibility, patient stratification and site selection. It is not a patient matching service.

So a report may hand you trial names, but a name is not eligibility and not a place in a study. The assessment still happens at a site, against the full protocol criteria.

Before paying for a panel, ask the trial team you are targeting which tests they require, which they accept from an outside laboratory, and whether they perform the testing themselves. Some protocols include molecular testing within screening, which can make a commercial panel unnecessary.

An independent second opinion

A second opinion is reasonable before committing to a next line of treatment, and it is often most useful from outside the team that wrote the current plan. Note that being at a different hospital does not by itself mean a reviewer has no competing interest, so the questions below are worth asking of anyone.

Dr Bharat Patodiya is a medical oncologist in Hyderabad holding MBBS, MD and DNB Medical Oncology qualifications, and, according to his own practice site, a certificate of competence in breast cancer from Ulm, Germany. He reviews plans and pathology where treatment is already under way elsewhere.

Two caveats. Published directory listings disagree about his years of practice and current hospital affiliations, so verify registration with the relevant State Medical Council or the National Medical Commission and confirm the rest with the practice directly. And an independent practice is not a trial site: a second opinion can identify a specific trial worth asking about, but enrolment happens at a centre running the study.

What being in a trial actually involves

Expectations here are often set by news coverage rather than by protocols.

Phases differ enormously. A Phase I study is primarily about dose and safety, often in people who have exhausted standard options, and the chance of individual benefit is genuinely low. Phase II asks whether a signal of activity exists. Phase III compares a new approach against current standard care to establish comparative efficacy and safety, and whether it is actually better is the question the trial exists to answer. Phase IV follows an already-approved drug. Asking which phase a protocol is, and what its primary endpoint measures, tells you more about your likely experience than the drug name does.

Phase	What it is testing	What it means for you
I	Dose and safety, often in people who have exhausted standard options	Individual benefit is genuinely uncommon; the question being answered is about tolerability
I/II	Dose finding plus an early look at activity	Intensive monitoring, small numbers, outcome uncertain
II	Whether a signal of activity exists in a defined group	Often single-arm, so everyone receives the investigational treatment
III	The new approach against current standard care, to establish comparative efficacy and safety	Usually randomised, though not always; whether the new approach is better is the open question
IV	An already-approved drug in wider use	Closest to ordinary treatment, with extra data collection

Randomisation means you may receive standard care. In oncology you are very rarely given a placebo alone when an effective treatment exists; the usual comparison is new drug plus standard care against standard care, sometimes with a placebo added to blind it. Being in the control arm is not being untreated, but it is a real possibility you should have priced in.

Consent is ongoing and withdrawal is permitted. You can withdraw at any point and for any reason, and doing so must not be penalised or cost you care you would otherwise be entitled to. Ask in advance what the transition back to standard treatment looks like and what it will cost, since that is a separate question from the right to leave. A protocol that implies you cannot withdraw is a reason to walk away.

The visit schedule is usually heavier than standard treatment. Extra scans, extra blood draws, fixed visit windows, and a diary in some studies. For someone travelling from another city this is often the deciding factor rather than the medicine.

When an offer is not a trial

Misleading commercial offers exist, and advanced disease makes people easier to mislead. A few checks separate a registered study from something else using the word.

Ask for the registration number. A trial conducted in India is required to be registered with CTRI before enrolling its first participant. If nobody can give you a CTRI number, or the number does not resolve on the registry, you are not being offered a registered trial. A number is a starting check rather than a clearance, though: also confirm the site, the investigator, the ethics committee and the regulatory permission.

You should not be paying for the investigational drug. In a sponsored trial the sponsor funds the investigational agent and the protocol-mandated tests. An offer to "enrol" you in a trial in exchange for a fee for the experimental treatment is not how trials are funded, and it is the clearest signal to stop.

There must be a named ethics committee. Every registered trial has ethics committee approval, and the consent document should name the committee. It need not belong to that hospital: where a site has no committee of its own, a registered independent committee may take responsibility for it, and the rules require that committee to be in the same city or within 50 km. Ask which committee approved the protocol and request its name in writing. Regulatory permission applies where required, with a specific exemption for some academic trials, so ask which basis applies.

Written consent comes before anything happens. You should receive a participant information sheet in a language you read, have time to consider it, and keep a signed copy. Verbal reassurance in a consulting room is not consent.

Be wary of guaranteed outcomes. A protocol exists because the answer is not known. Anyone promising a response, a cure or a specific survival figure from an investigational treatment is describing something other than research.

This is also the right lens for "stem cell", "immune booster" and similar offerings sold as cutting-edge cancer treatment outside any registry. Unproven is not the same as promising, and paying for an unregistered intervention costs money that the ancillary expenses of a real trial would have needed.

Expanded access, which is a different route

If you do not meet the criteria for any open trial and standard options are exhausted, expanded access, also called compassionate use, is a separate mechanism rather than a variant of enrolment.

The treating hospital applies to the manufacturer for the drug, and in most cases to the Central Drugs Standard Control Organisation for permission to import or use it outside an approved indication. It is decided case by case, it is slow relative to how fast advanced disease moves, and there is no entitlement to it. Funding varies: the manufacturer sometimes supplies the drug without charge, and sometimes does not.

It is not an unmonitored free-for-all, which is a common misconception. India's route for supplying an unapproved drug requires medical supervision, records of the patient and dosage, and reporting of serious adverse events. What differs from a trial is that the arrangements are programme-specific rather than set by a protocol with a sponsor behind it. So ask explicitly who supplies and pays for the drug, who monitors for toxicity and how often, and what is reported to whom, and get the answers before agreeing.

After you make contact

Screening is its own phase and it is not a formality. Expect repeat imaging, fresh blood work, sometimes a new biopsy because the protocol needs tissue processed a particular way or tested in a specific laboratory, and a formal review against every inclusion and exclusion criterion. It commonly takes some weeks, and a screening failure at the end of it is a normal outcome rather than a sign anything went wrong. Ask the site for its own expected timeline.

Two things are worth asking at first contact rather than discovering later. The first is which screening investigations are routine care, billed as usual, and which are research-related: ICMR's ethical guidelines say participants should not bear research-related expenses beyond routine care, including work-up and investigations. The second is whether you are expected to pause current treatment during screening. A washout requirement during a screening period that then ends in a screening failure is the worst case, and it is foreseeable enough to ask about.

What actually decides eligibility

The criteria that most often decide the answer:

• Biomarker and receptor status. ER, PR, HER2, and increasingly PIK3CA, HRD, BRCA1/2 and PD-L1. Ask for the complete report, and for your clinician's reading of it rather than the figures alone.
• Prior treatment lines. Many protocols specify how many previous lines you may have had and which drug classes disqualify you, which is why the treatment timeline matters.
• Performance status. Usually ECOG, where a higher score means greater impairment and protocols set an upper limit, commonly 0 to 1 or 0 to 2. Ask which range a protocol permits.
• Organ function. Blood counts, kidney, liver and cardiac function against protocol thresholds.
• Washout periods. A minimum interval since your last treatment. This is worth raising early, because treatment timing and a possible trial have to be coordinated between your treating oncologist and the trial investigator. Preserving eligibility is never a reason to delay treatment you need on its own merits.
• Measurable disease. Many protocols need a lesion measurable on imaging to assess response.

Most adult protocols set a lower age bound, commonly 18. Upper limits are less common, with organ function and performance status usually carrying more weight, but this is protocol-specific and worth checking against the one you are considering.

What it costs, and what stops people

The usual split is that the sponsor funds the investigational drug and the tests the protocol mandates, while you carry travel, accommodation, caregiver time and lost income, plus any standard-of-care component that sits outside the protocol. Insurance generally excludes investigational treatment, and a verbal assurance from an insurer is not coverage. Get it in writing, naming the drug and the indication.

One entitlement is worth knowing: under India's New Drugs and Clinical Trials Rules, a participant injured in a clinical trial is entitled to free medical management, provided until the investigator judges it no longer necessary or the injury is established as unrelated to the trial, whichever comes first. Separately, financial compensation is payable for injury or death established as trial-related. The two are different entitlements with different tests. The consent documents should set them out and name who to contact; if they do not, ask before signing.

Reimbursement is not impossible, so ask rather than assume. ICMR's ethical guidelines expressly allow reimbursement of travel and incidental expenses and compensation for time, subject to ethics committee approval, so request the study's written reimbursement policy. Where that does not cover you, hospital social workers and institutional charitable funds are the practical next stop.

The file that decides how fast this moves

Whoever you approach can only work as fast as your documentation allows. Before the appointment, assemble:

• The complete histopathology report, including ER, PR and HER2 status
• Any genomic or biomarker testing, or an explicit note that none has been done
• Recent imaging, the images themselves and not only the reports
• A written treatment timeline: every line, with dates, and why each one stopped
• Current blood counts and organ function tests
• A plain note on current performance status, what you can and cannot do day to day
• Your shortlist of protocol numbers with the eligibility questions attached

Bringing this complete, rather than promising to email it, is what shortens the distance between a question and an answer.

Where else to ask

Three sources of help that cost nothing and get overlooked.

The hospital social worker or medical social services desk. Most large Indian cancer centres have one, and they can help identify institutional charitable funds and the state schemes you may qualify for. What any given desk can actually fund varies, so confirm directly rather than assuming. It is an underused route, mostly because patients are rarely told it exists.

Patient organisations. Groups focused on breast cancer in India run helplines and peer networks whose volunteers have been through screening and enrolment themselves. They cannot assess your eligibility, and another person's experience is not evidence about your case. What they can share is practical experience of travel, visit schedules and dealing with a given centre, which is worth having even though it needs confirming directly.

The study contact listed against the protocol. When a registry entry names a contact person, that is a legitimate route to ask whether a site is still recruiting and what the broad eligibility picture looks like. You do not need a referral to ask a factual question about recruitment status.

What none of these can do is tell you whether a specific protocol fits your disease. That assessment needs your full file in front of a clinician.

Limitations of this page

Recruitment status changes constantly, so every protocol mentioned anywhere on the internet, including here, should be re-checked at source before you act on it.

The institutional descriptions here come from each organisation's own published material, checked in November 2026. Service descriptions, contacts and capabilities change without announcement, and a few widely repeated claims about Indian trial infrastructure did not survive checking against primary sources, which is why some entries above are narrower than you will see them described elsewhere.

We have not independently audited any laboratory's accreditation, any centre's trial volume, or the concordance figures reported by any opinion service. Where a figure is a company's own, this page says so.

Frequently asked questions

Is there one place to search for Indian breast cancer trials? No. CTRI is the statutory Indian registry and the better record of investigator-initiated Indian studies; ClinicalTrials.gov is broader but lists many trials with no Indian site. Search both, then check the hospital's own list.

Does insurance cover a clinical trial? Generally not the investigational drug, which the sponsor usually funds. Standard-of-care components you would have needed anyway may be covered depending on your policy. Confirm in writing before enrolling.

Can I join a trial at a hospital in another city? Yes. Trials run site by site, and a referral from your oncologist is the normal route. Factor the travel and visit schedule in honestly, because that is what most often becomes unworkable.

What if recruitment closes while I am being screened? You will not be enrolled in that study. Ask the site directly to confirm your consent and enrolment status, what happens to investigations already under way, and what the immediate treatment plan is, rather than assuming an automatic handover. It is a common enough outcome to be worth checking recruitment status close to your appointment.

Is there an upper age limit? Often not, but it is protocol-specific. Most adult protocols set a minimum age and lean on organ function and performance status at the other end. Check the protocol you are considering.

Can I leave a trial partway through? Yes, at any point and for any reason, and withdrawal must not be penalised. Ask separately what the handover back to standard treatment involves and what it costs.

Will I get a placebo instead of treatment? Very unlikely to be a placebo alone where effective treatment exists. The usual design compares a new drug added to standard care against standard care, sometimes placebo-controlled to blind it. You should still assume the control arm is possible.

Does palliative care rule me out? Supportive and symptom care generally runs alongside a protocol rather than excluding you, but it is decided per protocol. The team will check for interactions with the investigational agent and confirm organ-function thresholds. Ask about the specific trial rather than assuming either way.

Should a second opinion come from my own hospital? It is more useful from outside it. An independent reviewer has no stake in the plan already running, and breast cancer decisions increasingly hinge on subtype detail a general review can pass over.

Nothing here is advice about your treatment. No page can tell you whether a trial fits you. Take your file and your shortlist to a qualified oncologist and ask the eligibility questions directly.

---

Reviewed 6 November 2026 by the India Cancer Guide editorial team. This article has not been reviewed by an independent clinician. Every claim about an organisation or regulation is cited to that body's own published material or to the relevant rules, and our sourcing policy sets out how those are chosen. Recruitment status, service terms and costs all change; if you find something stale or wrong, tell us and we will correct it and date the correction.